|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Childhood asthma
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations.
|
23829686 |
2013 |
|
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
Among patients with poor response to interferon therapy (<1-log(10) decline in HCV RNA at week 4), 39% in the BOC/PEG2a/R group had SVRs, compared with none of the patients in the PEG2a/R group.
|
23064222 |
2013 |
|
Leukopenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Fifty percent of patients in the BOC/PEG2a/R group developed anemia (hemoglobin <10.0 g/dL), compared with 27% in the PEG2a/R group; 43% vs 21%, respectively, developed neutropenia (neutrophil count <750/mm(3)).
|
23064222 |
2013 |
|
Neutropenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Fifty percent of patients in the BOC/PEG2a/R group developed anemia (hemoglobin <10.0 g/dL), compared with 27% in the PEG2a/R group; 43% vs 21%, respectively, developed neutropenia (neutrophil count <750/mm(3)).
|
23064222 |
2013 |
|
anemia hemoglobin
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fifty percent of patients in the BOC/PEG2a/R group developed anemia (hemoglobin <10.0 g/dL), compared with 27% in the PEG2a/R group; 43% vs 21%, respectively, developed neutropenia (neutrophil count <750/mm(3)).
|
23064222 |
2013 |
|
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
The secondary objective was the evaluation of the percent of patients with negative HCV RNA at week 4 (RVR), 8 (RVR BOC), 12 (EVR), or at the end-of-treatment (ETR) that reached SVR.
|
25469044 |
2014 |
|
Leukopenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Nausea, diarrhoea and neutropenia were the only other common events with an incidence of at least 5% greater when BOC was added to the PR backbone.
|
24118703 |
2014 |
|
Neutropenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Nausea, diarrhoea and neutropenia were the only other common events with an incidence of at least 5% greater when BOC was added to the PR backbone.
|
24118703 |
2014 |
|
Anemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Only two adverse events, anaemia and dysgeusia, occurred 20% more often with the BOC-containing regimens compared with PR.
|
24118703 |
2014 |
|
Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that BOC is upregulated in medulloblastomas and induces GCP proliferation.
|
25263791 |
2014 |
|
Hepatitis C, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribavirin.
|
24362076 |
2014 |
|
Compensated cirrhosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
|
26670100 |
2015 |
|
Gastrointestinal Stromal Tumors
|
0.300 |
Biomarker
|
group |
CTD_human |
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
|
27793025 |
2016 |
|
Gastrointestinal Stromal Sarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
|
27793025 |
2016 |
|
Hepatitis C
|
0.040 |
Biomarker
|
disease |
BEFREE |
The UDPS follow-up analysis demonstrated that the presence of BOC or TLP-RAVs persist one year after therapy cessation only in HCV GT 1a patients.
|
26971166 |
2016 |
|
Hepatitis C
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules).
|
27990835 |
2017 |
|
Embryonal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate that BOC and ABL are induced in P19 embryonal carcinoma (EC) cells and cortical neural progenitor cells (NPCs) during neuronal differentiation.
|
27871935 |
2017 |
|
Portal Hypertension
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules).
|
27990835 |
2017 |
|
Liver Cirrhosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules).
|
27990835 |
2017 |
|
Holoprosencephaly
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we report the identification of missense BOC variants in HPE patients.
|
28677295 |
2017 |
|
Cirrhosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules).
|
27990835 |
2017 |
|
Colorectal Neoplasms
|
0.410 |
Biomarker
|
group |
BEFREE |
Thus, the pH-activatable SN-38-BOC micelle could serve as a promising candidate in colorectal tumor therapy.
|
31352923 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Colorectal Neoplasms
|
0.410 |
GeneticVariation
|
group |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |